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Abstract
Tumour microenvironments are hallmarked in many cancer types. In haematological 
malignancies, bone marrow (BM) mesenchymal stromal cells (MSC) protect malignant cells 
from drug-induced cytotoxicity. However, less is known about malignant impact on supportive 
stroma. Notably, it is unknown whether these interactions alter long-term genotoxic damage 
in either direction. The nucleoside analogue cytarabine (ara-C), common in haematological 
therapies, remains the most effective agent for acute myeloid leukaemia, yet one-third of 
patients develop resistance. This study aimed to evaluate the bidirectional effect of MSC and 
malignant cell co-culture on ara-C genotoxicity modulation. Primary MSC, isolated from patient 
BM aspirates for haematological investigations, and malignant haematopoietic cells (leukaemic 
HL-60) were co-cultured using trans-well inserts, prior to treatment with physiological dose 
ara-C. Co-culture genotoxic effects were assessed by micronucleus and alkaline comet assays. 
Patient BM cells from chemotherapy-treated patients had reduced ex vivo survival (P = 0.0049) 
and increased genotoxicity (P  =  0.3172) than untreated patients. It was shown for the first 
time that HL-60 were protected by MSC from ara-C-induced genotoxicity, with reduced MN 
incidence in co-culture as compared to mono-culture (P  =  0.0068). Comet tail intensity also 
significantly increased in ara-C-treated MSC with HL-60 influence (P = 0.0308). MSC sensitisation 
to ara-C genotoxicity was also demonstrated following co-culture with HL60 (P = 0.0116), which 
showed significantly greater sensitisation when MSC-HL-60 co-cultures were exposed to ara-C 
(P = 0.0409). This study shows for the first time that malignant HSC and MSC bidirectionally 
modulate genotoxicity, providing grounding for future research identifying mechanisms 
of altered genotoxicity in leukaemic microenvironments. MSC retain long-term genotoxic 
and functional damage following chemotherapy exposure. Understanding the interactions 
perpetuating such damage may inform modifications to reduce therapy-related complications, 
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Introduction
Disease progression mediated by the bone marrow (BM) micro-
environment is a recognised contributor in many haematological 
malignancies (HMs) (1–3). Mesenchymal stromal cells (MSC) play 
a critical role in haematopoiesis within this microenvironment, by 
providing both a physical supportive infrastructure and by secre-
tion of cytokines, growth factors and adhesion proteins for haem-
atopoietic stem cells (HSC) (2,4). It is therefore also permissive of 
the progression and protection of HMs—which develop through 
transformation of HSC—in its ideal, nutrient-rich environment 
(5–8).
HMs encompass many complex disorders, for which biological 
and clinical heterogeneity present great difficulties in diagnosis and 
treatment, compounding diverse clinical outcomes (9,10). A shared 
feature of all HMs is their proximity within the BM microenvir-
onment and therefore the interaction with MSC (1,5). Commonly, 
these malignancies are characterised by accumulation of dysfunc-
tional, immature leukocytes/HSC in the BM and peripheral blood, 
hindering the proliferation of normal mature haematopoietic 
cells (11). Studies have revealed abnormal BM niche properties 
in many of these cancers (12), including leukaemia (13–15), mul-
tiple myeloma (MM) (16,17) and lymphoma (18,19). However, 
this crosstalk is still poorly understood and requires further in-
vestigation, especially since extremely poor clinical outcomes are 
attributed to intolerance to treatment toxicity in less biologic-
ally fit patients, chemoresistance (20,21) and perhaps the tumour 
microenvironment.
Up to one-half of patients with acute myeloid leukaemia (AML), 
for example, do not show continued response to the mainstay of 
leukaemia therapies, cytarabine (ara-C) (22,23). Ara-C is a widely 
utilised clastogenic agent that induces chromosomal aberrations and 
inhibits normal DNA repair mechanisms (24). Genotoxicity by pre-
vious treatment such as ara-C, or interactions with an aberrant BM 
microenvironment, may be implicated in post-treatment BM failure 
after allogeneic stem cell transplantation (alloSCT) (25), and the 
higher incidences of secondary malignancies seen in patients treated 
years previously (26).
Secondary malignancies are a common complication of HM 
therapies (27–30), including alkylating agents, anthracyclines, topo-
isomerase inhibitors (31), antimetabolite drugs and radiotherapy 
(27). The incidence of secondary solid tumours in those treated 
with high-dose ara-C was greater than 2-fold at 10 years, as com-
pared to those treated without high-dose ara-C (32). Additionally, 
AML/myelodysplastic syndrome (MDS) were more common in 
HM patients who received autologous SCT than those treated 
without SCT (28), explained by preparative myeloablation by total 
body irradiation (28). Additionally, the risk of second malignan-
cies was shown to increase with rituximab-based treatment stage 
in follicular lymphoma patients (29). This may be attributed to the 
lasting genotoxic damage that chemo/radiotherapy produces; with 
MSC shown to retain long-term genotoxic and functional damage 
years following chemotherapy (33,34). Importantly, MSC remain of 
host-origin post-alloSCT, rather than replacement by donor cells fol-
lowing myeloablation (35). MSC are, therefore, susceptible to DNA 
damage accumulation/genomic instability due to prolonged lifespan, 
and mutations from these previous exposures (36); enabling charac-
teristics for further tumourigenesis (37).
Numerous studies have shown that leukaemic cells co-cultured 
with stromal cells are less sensitive to the cytotoxic effects of chemo-
therapy, with increased apoptosis avoidance (38,39), increased 
leukaemic cell growth (40,41) and altered phenotypic expression 
(2,13,42). Other studies have also shown that MSC in patients with 
a HM are functionally altered (13,43,44); however, there is sig-
nificantly less research focus on the impact of disease on the BM 
stroma itself.
Despite the potential gravity of lasting genotoxic damage in the 
clinical setting, there are no known studies to date which focus on 
the bidirectional modification of genotoxicity in response to treat-
ment by the leukaemic microenvironment. The complex nature of 
haematopoietic disease, the BM microenvironment itself and their 
understudied relationship warrants further research. Better under-
standing of these mechanisms could improve the long-term recovery 
and complications caused by malignancy and chemotherapeutic 
treatments to the BM. This pilot study, therefore, aimed to evaluate 
the effect of co-culture of heterogeneous primary BM–MSC (from 
patients recently diagnosed either with a primary HM or subsequent 
to prior chemotherapy) and malignant HSC on genotoxicity, in both 
cell types post-ara-C exposure.
Materials and Methods
Cell culture
Sample collection. BM aspirate samples were obtained from patients 
undergoing routine investigations for the diagnosis or monitoring 
of a haematological disease at the Royal United Hospitals NHS 
Foundation Trust, Bath, following donor consent and NHS ethics 
approval (18/NI/0036). BM aspiration was performed by clinical 
professionals from the iliac crest and collected into sterile lithium 
heparin sample tubes. Details of samples for co-culture analyses in 
this study are shown in Table 1, with full sample details shown in 
Supplementary Table I, available at Mutagenesis Online.
Mononuclear cell isolation. The mononuclear cell (MNC) frac-
tion was isolated from BM aspirates by density gradient centri-
fugation, as previously described (34). Samples were diluted 1:1 
with low glucose (LG; 1,000  mg/l) Dulbecco’s Modified Eagle’s 
Medium (DMEM) before gentle layering onto an equal volume of 
Histopaque-1077 (density 1.077  g/ml). Cells were centrifuged at 
600 × g for 20 min without brakes. MNC fraction was washed in 
MSC medium (LG-DMEM supplemented with 10% foetal bovine 
serum (FBS; STEMCELL Technologies, Cambridge, UK) and 2 mM 
l-glutamine). Residual erythrocytes were removed by resuspension 
Table 1. Summarised characteristics of patients from which BM 
samples were used for co-cultures
Characteristic n = 22 %
Age (years)   
Median (range) 68.5 (36–90)  
Gender   
Female:male 11:11 50:50
Treatment   
Untreated:treated 18:4 82:18
Diagnosis   
AML (at diagnosis) 3 13.6
AML (post-treatment) 2 9.1
Other HM (at diagnosis) 13 59.1
Other HM (post-treatment) 2 9.1
No HM 2 9.1
HM, haematological malignancy.
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in red cell lysis buffer (150 mM NH4Cl, 100 mM NaHCO3, 1.3 mM 
EDTA) for 5 min and washed in MSC medium.
MSC culture. MNC were seeded at 4 × 105/cm2 in MSC medium 
and incubated at 37°C/5% CO2. After 3  days, non-adherent 
haematopoietic cells were replaced with fresh medium, with cultures 
maintained by weekly demi-depletion until 70% confluency was 
reached. Cells were passaged with trypsin (0.05% trypsin/0.02% 
EDTA) and reseeded at 4 × 103/cm2 (passage one; P1) and for all 
further passages. Cells were cryopreserved (MSC medium containing 
25% FBS and 10% DMSO) in liquid nitrogen vapour-phase at the 
end of P1, resuscitated and experimental work performed at P4. 
Purity of MSC cultures was confirmed by immunophenotype and 
differentiation capacity; at the same passage as experimentation 
(P4) and according to international guidelines (45). Confirmatory 
immunophenotyping was achieved on all samples using the Human 
MSC Phenotyping Kit (Miltenyi Biotec, Woking, UK) according 
to manufacturer’s instructions, staining positively for CD73-APC, 
CD90-FITC and CD105-PE, and negatively for CD14-PerCP, CD20-
PerCP, CD34-PerCP and CD45-PerCP (data not shown). MSC from 
three independent cultures (011B, 016, 025) were also induced to 
undergo tri-lineage differentiation using StemPro® Differentiation 
Kits (Thermo Fisher Scientific) for adipogenesis, chondrogenesis 
and osteogenesis, according to manufacturer’s instructions (data not 
shown).
Leukaemic-stromal co-cultures. Patient MSC (5 × 104) were seeded 
in 3.8-cm culture plates and allowed to adhere for 24 h. The AML 
cell line, HL-60 (ATCC® CCL240™) (1  × 105), was seeded into 
0.4  µm pore hanging cell culture trans-well inserts (Millipore UK 
Ltd., Watford, UK) above the stromal layer in the co-culture model 
(Figure 1). HL-60 were selected due to previously determined ara-C 
sensitivity (46) and to represent a constant HSC variable in the model. 
Cells were co-cultured for 24 h, with addition of 25 µM ara-C for 
the final 1 h, relevant to the clinical standard dose of 100–200 mg/
m2 (47). Dose conversion was calculated based on an average person 
weighing 70 kg, equivalent to 50 l total body volume and 1.79 m2 
total surface area. Cells were separated from co-culture and manually 
counted with addition of 0.4% trypan blue, from which cell viability, 
population doubling (PD) and relative increase in cell count (RICC) 
were determined, as per OECD guidelines prior to genotoxicity 
analysis (48) and detailed by Fellows et al. (49).
Micronucleus assay. Cells were washed following co-culture and 
treatment and returned to culture in fresh medium for 48  h as 
per OECD guidelines for micronucleus (MN) assays without 
Cytochalasin B, requiring 1.5–2 cell divisions post-treatment. Cells 
were harvested, washed and 5  × 104 cells in 150  µl phosphate 
buffered saline (PBS) loaded into Shandon™ Cytofunnel™ (Life 
Technologies, Inchinnan, UK) and mounted to polished glass slides 
by Cytospin™ 4 (Life Technologies) centrifugation at 1000  rpm 
for 10  min with high acceleration. Mounted cells were fixed 
using 100% methanol for 8 min with washes in phosphate buffer 
(pH 6.4–6.5; 0.66% KH2PO4, 0.33% Na2HPO4). For staining, 
slides were dipped briefly in phosphate buffer before exposure 
to 0.12  mg/ml Acridine Orange for 45  s, then finally washed in 
phosphate buffer. Slides were imaged by fluorescence microscopy 
(Nikon Eclipse 80i; Nikon, Tokyo, Japan) and NIS-Elements 
software (Nikon) under triple band-pass filter and manually scored 
for mononucleated, MN, binucleated, apoptotic, lobed, notched 
and multinucleated cells.
Alkaline comet assay. Co-cultured cells (5  × 104) were washed in 
PBS and 40-µl mounted onto Gelbond® film (Lonza, Slough, UK) 
in 0.5% low-melt agarose. Positive control gels were prepared 
simultaneously by treatment with 50 µM H2O2 for 10 min. All gels 
were lysed (2.5 M NaCl, 100 mM EDTA disodium salt, 10 mM Tris, 
1% Triton X-100, 10% DMSO) for >1 h and exposed to alkaline 
electrophoresis buffer (pH 13; 1 mM EDTA, 300 mM NaOH) for 
20 min to unwind the DNA. Gels were electrophoresed for 20 min (1 
V/cm, 300 mA) and washed in neutralisation buffer (pH 7.5; 0.4 M 
Tris). Immediately prior to imaging, slides were stained with 20 µg/
ml propidium iodide and cells imaged by fluorescence microscopy 
(Nikon 80i) under Texas red filter and NIS-Elements software 
(Nikon) and scored for % DNA in the tail (tail intensity %) using 
Comet Assay IV software (Perceptive Instruments Ltd., Bury St. 
Edmunds, UK). Further details of experiment protocols can be found 
in the supplement, as per the Minimum Information for Reporting 
on the Comet Assay (50).
Statistical analysis
All statistical tests were performed in GraphPad Prism 9. One-way 
ANOVA was performed for comparison of three or more groups, fol-
lowed by a post hoc test to define differences between groups. T-test 
was used to define differences between two groups. In all cases, stat-
istical significance was assumed where P  < 0.05. For each patient 
co-culture, MN incidence was calculated as a % of total scored cells, 
from which the % change between alone and co-culture groups, or 
mean MN incidence, was plotted for analysis. The median comet 
tail intensity (%) was calculated for each patient co-culture, repre-
senting the experimental unit (51). The % change between alone and 
co-culture groups, or mean tail intensity, was then plotted from me-
dian values for analysis. In the MN assay, 2000 cells were scored 
for each treatment group, while 200 cells were scored for the comet 
assay, whenever possible, as recommended by the genotoxicology 
testing guidelines in place when experimental work was undertaken 
(48,50,52).
Fig. 1. Schematic of co-culture and treatment for genotoxicity assessments. 
Cells were cultured alone or in co-culture, separated by a cell culture insert 
(A). Following 24 h in co-culture (or culture alone), both MSC and HL-60 cells 
were treated with ara-C and cells harvested for comet assays, or returned 
to culture in fresh medium for a recovery period, after which both MSC and 
HL-60 cells were harvested for micronucleus (MN) assays (B).
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Results
Primary BM cells from chemotherapy-treated 
patients have reduced ex vivo survival and those 
which did not expand ex vivo have increased 
genotoxicity
The influence of genotoxicity from prior chemotherapy and ex 
vivo cell survival was assessed in primary patient BM cells. Patient 
BM-MNC cultures from previously treated individuals were signifi-
cantly less likely to expand ex vivo, with survival at P4 (the point 
at which MSC cultures are considered ‘pure’ by standard isolation 
methods, and can therefore be utilised in experiments) significantly 
lower than samples taken from patients at diagnosis (P = 0.0049; 
Figure 2A). This was hypothesised as extensive impact on cellular 
function from the patient’s disease and/or prior treatment. The cul-
tures which did not expand ex vivo were analysed by the alkaline 
comet assay, with more damaged DNA seen within the tail in cells 
from individuals who had previously been treated with chemo-
therapy, as compared to untreated patients at diagnosis (P = 0.3172; 
Figure 2B and C).
Primary MSC may be sensitised to ara-C-induced 
genotoxicity in co-culture with leukaemic HL-60 
cells, while the leukaemic cells appear protected
A co-culture system was designed to enable study of bidirectional 
effects, following in vitro ara-C treatment of primary MSC and a 
leukaemic cell line (representing a constant HSC variable; Figure 
1A). This co-culture model was utilised to mimic the haematopoietic 
tumour microenvironment, whereby malignant HSC (HL-60) and 
MSC interact in the BM via soluble factors, as one such crosstalk 
mechanism (2,53).
Genotoxicity was investigated by the measurement of division 
abnormalities in the MN assay, following a 48-h recovery period 
post-treatment in vitro (Figure 1B), in accordance with the OECD 
guidelines which recommend testing after 1.5–2 PD (48) (Table 2). 
Ara-C treatment equivalent to standard in vivo dose (100–200 mg/
m2) was utilised for a 1-h period to ensure that cytotoxicity did not 
exceed OECD recommended levels, with maximum cytotoxicity/
viability reduction of 28.9% following recovery (Table 2). In MN 
assessments omitting the use of Cytochalasin B, as in this study, it is 
recommended to use RICC as a measure of cytotoxicity (54), with 
relevant data for cell cultures used in this study shown in Table 2. 
Mean RICC was acceptable (>55% ± 5%) for co-cultured HL-60 
cells, MSC cultured alone and in co-culture; however, HL-60 cells 
cultured alone had mean RICC < 55% ± 5% (42.4%; Table 2).
The effect of MSC-HL-60 co-culture and ara-C treatment on 
genotoxicity was assessed in leukaemic-stromal co-cultures by meas-
urement of MN incidence (Figure 3). In MSC, the MN incidence in 
in vitro ara-C-treated cultures was shown to be marginally altered 
overall, with a mean % change of 0.255% from MSC cultured alone 
to co-culture with HL-60 (P = 0.1942; Figure 3A). However, MN in-
cidence in these ara-C-treated HL-60 cells was significantly reduced 
Fig. 2. Survival of primary BM cultures and genotoxicity of those which did not expand ex vivo. Primary BM-MNC were cultured in standard conditions. (A) 
Kaplan–Meier survival was plotted for cultured BM cells from patients previously untreated/at diagnosis (n = 23; dashed line) or treated with chemotherapy for 
a haematological malignancy (n = 10; solid line) from passage 0 to 4. (B) Patient cultures which did not expand were categorised into untreated or previously 
treated, prior to assessment of comet tail intensity, alongside negative (Neg.; untreated HL-60 cells) and positive (HL-60 treated with H2O2) controls. Bars represent 
mean (± SD) of median tail intensity (%) from each experimental unit (patient culture). Untreated; n = 5 (mean 202 cells scored per patient culture), treated; n = 6 
(mean 175 cells scored per patient culture). (C) Examples of scored cells for each experimental group (Comet IV software). Untreated; ID 027, Treated; ID 028.








utage/geab033/6368295 by guest on 05 O
ctober 2021
following co-culture with patient MSC, with a mean % change of 
−0.827% from culture alone to co-culture (P = 0.0068; Figure 3A). 
This indicates for the first time that leukaemic HSC may be pro-
tected by MSC from ara-C-induced genotoxicity.
The heterogeneity of MN as a measure of genotoxicity in these 
co-cultures was assessed in MSC (Figure 3B) and HL-60 cells (Figure 
3C). Treatment with a physiological dose of ara-C only minimally 
increased MN incidence in MSC from all individuals analysed 
(Figure 3B, P = 0.096). Following in vitro ara-C treatment, MN in-
cidence in MSC was further increased between untreated MSC cul-
tured alone and when co-cultured with HL-60 cells; an effect seen 
in 17 of the 22 co-cultures (P = 0.0293; Figure 3B). This increase 
in MN between treated MSC cultured alone and in co-culture did 
not reach statistical significance overall (P = 0.858; Figure 3B). This 
demonstrates heterogeneity of MSC response to ara-C and malig-
nant HSC influences, as well as some resistance against the genotoxic 
effects of ara-C subjection. Conversely, in vitro ara-C treatment sig-
nificantly increased MN incidence in all HL-60 cultures, both in 
mono-culture (P < 0.0001) and co-culture with MSC (P < 0.0001), 
with mean 2.33-fold and 1.99-fold increase, respectively (Figure 
3C). This increase was, however, attenuated by co-culture with the 
vast majority of primary MSC samples with a 1.17-fold reduction 
(P = 0.101). This resulted in a statistically significant reduction in 
MN % change between treated HL-60 alone and in co-culture with 
MSC (P = 0.0068; Figure 3A). These results demonstrate both ara-C 
sensitivity in HL-60 cells and some preservation by MSC.
Genotoxicity was also assessed by the alkaline comet assay in 
MSC and HL-60 cells following treatment and co-culture (Figure 
4), as MN formation and DNA fragmentation are recognised gold-
standard genotoxicity measures in mammalian cells (55). In order to 
account for high variation between individuals, median % change 
in tail intensity between alone and co-culture was calculated. 
Comet tail intensity in untreated MSC was shown to not change 
following co-culture with HL-60, with a mean change of 0.0454% 
(P  =  0.0844; Figure 4A). However, MSC treated with ara-C in 
co-culture with HL-60 showed a significant increase in tail intensity, 
with a mean change of 0.902% in co-culture (P = 0.0116; Figure 4A). 
Interestingly, MSC were sensitised to ara-C-induced genotoxicity 
with HL-60 as compared to untreated co-culture (P = 0.0409). Both 
untreated and ara-C-treated HL-60 showed a mean reduction in tail 
intensity when co-cultured with MSC (−0.5858%, P = 0.0753 and 
−0.3897%, P = 0.2969, respectively; Figure 4B), with no significant 
difference between the effect of co-culture in in vitro untreated and 
ara-C-treated cells (P = 0.7601).
Visualisation of changes in genotoxic response following 
co-culture in individual patient co-cultures demonstrated evident 
heterogeneity in both MSC (Figure 4C) and HL-60 (Figure 4D) re-
sponse. Tail intensity was shown to increase in only 10 of 22 un-
treated MSC co-cultures (P = 0.4176) and 14 of 22 ara-C-treated 
co-cultures with HL-60 (P = 0.0308; Figure 4C), demonstrating a 
Table 2. Mean genotoxicity and corresponding cytotoxicity of ara-C treatment in patient MSC and HL-60 co-cultures
Group Ara-C 
(µM)
Mean MN % 
(SD)
Viability 1 h 
+ 1.5–2 PD% 
(SD)
RICC (SD) PD (SD) Mean scored 
(MN)
Mean comet tail 
intensity % (SD)





HL-60 alone 0 2.47 (0.79) 92.8 (4.0) 100 (0.0) 3.7 (2.4) 1923 3.26 (2.26) 87.1 (7.0) 214 22
25 5.76 (1.25) 71.1 (11.5) 42.4 (25.9) 1.7 (0.5) 1689  4.07 (3.38) 85.7 (8.6) 201 22
HL-60 co-culture 0 — 92.5 (3.3) 100 (0.0) 3.5 (1.6) — 2.67 (1.94) 86.3 (7.0) 208 22
25 4.91 (1.77) 84.2 (11.1) 60.0 (37.0) 2.4 (2.1) 1608 3.68 (2.89) 86.2 (8.4) 208 22
MSC alone 0 2.52 (1.19) 80.5 (9.7) 100 (0.0) 1.8 (0.6) 1534 3.44 (1.91) 82.0 (10.2) 190 22
25 3.58 (1.69) 82.4 (10.3) 96.9 (63.3) 1.7 (0.7) 1571 4.95 (2.57) 81.7 (8.2) 169 22
MSC co-culture 0 — 78.4 (10.9) 100 (0.0) 1.7 (0.8) — 3.65 (2.16) 80.1 (8.4) 182 22
25 3.83 (1.79) 76.7 (11.6) 95.0 (74.0) 1.7 (0.7) 1346 5.86 (2.84) 80.3 (10.6) 193 22
MN, micronucleus; PD, population doubling; RICC, relative increase in cell count.
Fig. 3. Genotoxicity in MSC/HL-60 in co-culture following in vitro ara-C 
treatment. Primary MSC and HL-60 cells were cultured alone or in co-culture 
±) using inserts for 24 h prior to treatment with ara-C (25 µM) for 1 h. The 
MN assay was performed on cells after a further 1.5–2 PD (48  h). Data 
represent MN incidence; as % change of ara-C-treated cells between alone 
and co-culture, box and whisker with min and max of all data points (A); 
as % of total scored cells, for untreated cells alone, treated cells alone, and 
treated cells following co-culture (B/C), for MSC (± HL-60) (B) and HL-60 (± 
MSC) (C). Bars represent the mean MN incidence from each experimental 
unit (patient culture) (B and C). Data shown for independent co-cultures of 
HL-60 and MSC samples from patients (n = 22), where for each patient sample 
co-culture experiment, 2000 cells were scored per treatment group where 
possible (mean number of cells scored shown in Table 2).
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significant increase in tail intensity when MSC were co-cultured 
with HL-60 and ara-C-treated. In HL-60 cells, tail intensity was de-
creased in 14 of 22 untreated co-cultures (P = 0.0501) and 12 of 
22 ara-C-treated co-cultures (P = 0.2969; Figure 4D). Variability in 
genotoxicity modulation highlights the challenge of distinguishing 
the impact of disease itself on the BM microenvironment
Sub-analyses of genotoxicity measures following co-culture of 
patient MSC and HL-60 cells were performed for the effect of prior 
chemotherapy treatment and the effect of patient AML/MM diag-
nosis (Supplementary Figure 1, available at Mutagenesis Online). 
Prior chemotherapy treatment was classified as those untreated due 
to no HM (no HM), those untreated at diagnosis for a HM (HM 
untreated) and those who had received prior chemotherapy treat-
ment for a HM (HM treated) (Supplementary Figure 1A, available 
at Mutagenesis Online). Overall, the most marked effects between 
cells cultured alone to co-culture were seen in MSC from HM un-
treated patients co-cultured with HL-60 cells, and in HL-60 cells 
co-cultured with MSC from no HM patients (Supplementary Figure 
1A, available at Mutagenesis Online). AML and MM patient cells 
were the focus of patient diagnosis assessment due to particularly 
poor in vitro cell survival (Figure 2; Supplementary Table I, available 
at Mutagenesis Online). Overall, an increase in ara-C genotoxicity 
in MSC by co-culture with HL-60 was similar when from AML and 
MM patients; however, HL-60 cells were greater protected when 
co-cultured with AML–MSC than with MM–MSC (Supplementary 
Figure 1B, available at Mutagenesis Online).
Together, these data suggest for the first time that HM patient 
MSC may be sensitised to ara-C genotoxicity by malignant HSC, 
while malignant HSC appear protected from the same effects, 
however, with heterogeneous responses mimicking those known 
clinically.
Discussion
This study aimed to evaluate the effect of chemotherapy exposure 
and co-culture of primary BM–MSC and leukaemic cells on 
genotoxicity, in both cell types. Modulation of chemotherapy agents’ 
genotoxic effects in MSC is a meaningful clinical issue. Secondary 
malignancy complications are prominent post-treatment for a HM 
(26,56,57), and poor haematopoietic function can have catastrophic 
impact on the ability to continue treatment and can, therefore, re-
duce the patient’s quality of life and survival outcome (58).
Some communications in the field suggest MSC to be a robust and 
drug-resistant cell type (36,59,60), which must be partly the case as 
MSC withstanding myeloablative chemotherapy are not replaced in 
the BM niche by donor MSC post-alloSCT (35,61). On the contrary, 
Fig. 4. Genotoxicity in MSC/HL-60 following co-culture and in vitro ara-C treatment. Primary MSC and HL-60 cells were cultured alone or in co-culture using 
inserts for 24 h prior to treatment with ara-C (25 µM) for 1 h. Genotoxicity was determined by alkaline comet assay. Data represent comet tail intensity; as % 
change of untreated or ara-C-treated cells between alone and co-culture, box and whisker with min and max of all data points, for MSC (± HL-60) (A) or HL-60 
cells (± MSC) (B); or as median % tail intensity for untreated or ara-C-treated cells alone, or following co-culture (C and D) for MSC (± HL-60) (C) and HL-60 cells 
(± MSC) (D). Bars represent mean of median tail intensity (%) from each experimental unit (patient culture). Data shown for independent co-cultures of HL-60 
and MSC samples from patients (n = 22), where for each patient sample co-culture experiment, 200 cells were scored per treatment group where possible (mean 
number of cells scored shown in Table 2).
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MSC are known to be damaged by a host of chemotherapeutic 
agents (44,62), importantly with impairments to normal function in 
the BM (33,34,63). Altered expression of adhesive CD44 (63) and 
morphological changes to MSC (33) have been shown post-exposure 
to chemotherapy, including cyclophosphamide and melphalan, com-
monly used in treatment of HMs. Our group have previously shown 
persisting genotoxicity in both the HS-5 stromal cell line and cord 
blood MNC (which are partially MSC constituted) following cyclo-
phosphamide treatment in appropriate metabolic models (34). In 
another study, BM-MSC and colony-forming unit fibroblast num-
bers were reduced up to one year post-SCT, where patients received 
high-dose ara-C consolidation chemotherapy and myeloablative 
busulfan/cyclophosphamide to prepare for the incoming graft (64). 
Our group further demonstrated persistence of genotoxic damage 
in patient MSC, even up to 17 years following cessation of chemo-
therapy for a HM (34).
These findings compliment those of this pilot study, whereby pri-
mary MSC which did not expand in vitro had significantly lower sur-
vival and increased genotoxicity when from patients who previously 
received in vivo chemotherapeutic treatment (Figure 2); potentially 
explained by defects in DNA damage response (DDR), replication 
stress pathways or genomic instability/DNA damage (65). Poor sur-
vival of cells from heavily treated individuals was overcome experi-
mentally to some extent by performing the comet assay on failing 
cultures in the first passage (Figure 2). These failed cultures (n = 11), 
subsequently analysed for genotoxicity, originated from both treated 
(n = 5) and untreated patients (n = 6), demonstrating that factors 
beyond just chemotherapeutic damage are at play in MSC health. 
Notably, cells from patients with AML and MM made up ten of the 
11 failed cultures (Supplementary Table I, available at Mutagenesis 
Online), both diseases with significant BM involvement. Damaged 
MSC may harbour mutations and have impaired ability to support 
normal haematopoiesis (33), inducing these secondary malignancies 
and BM failure in surviving patients (25). Reduced microenviron-
ment function and consequent haematopoietic failure may ultimately 
explain poor therapeutic efficacy in patients with haematological 
disease and warrants further research.
The effect of co-culture of MSC and malignant HSC on ara-
C-induced genotoxicity was assessed by measurement of MN 
formation (Figure 3) and DNA fragmentation (Figure 4), using a 
trans-well model to replicate bidirectional leukaemic-stromal inter-
actions (Figure 1). Primary patient MSC (the variable of focus) were 
co-cultured with the HL-60 cell line, since leukaemic cell lines do 
not require the support of a stromal feeder layer for survival in vitro, 
unlike primary HSC/leukaemic cells (66,67). Cells in the co-culture 
model were treated with the nucleoside analogue clastogen ara-C 
(24), commonly administered in combined therapies for acute leu-
kaemias and lymphoma (68). Ara-C inhibits the gap-filling step of 
excision repair, resulting in single-strand breaks at these sites and 
chromosome breaks/MN at the next cellular division (69,70). DNA 
repair and the rejoining of DNA strand breaks formed by other 
agents are also inhibited (71), as well as inhibiting polymerases 
during normal DNA replication (71). This agent, therefore, was 
used to assess the modulation of genotoxicity by MSC and malig-
nant HSC in co-culture, by measure of MN formation and DNA 
fragmentation.
A significant decrease in MN incidence in HL-60 cells following 
co-culture with MSC (Figure 3A; P = 0.0068) indicates for the first 
time that leukaemic cells may be protected from ara-C-induced 
genotoxicity by MSC. Our pilot study also showed a trend of de-
creased tail intensity overall in HL-60 following co-culture with 
MSC (Figure 4B and D). This concurs with one previous study 
showing BM-MSC to provide protection of the U266 MM cell line 
from melphalan-induced genotoxicity (72). There are few studies 
of this kind on genotoxicity modulation, while numerous reports 
have shown that the BM is able to provide protection from the cyto-
toxic effects of a number of agents at a cellular level (13,38–42,53). 
There was also a non-significant increase in MSC MN incidence 
following co-culture with HL-60 (Figure 3), while comet tail inten-
sity significantly increased in MSC following in vitro ara-C treat-
ment and co-culture with HL-60 (Figure 4A; P  =  0.0116, Figure 
4C; P  =  0.0308). Another study showed that the ability of MSC 
to protect leukaemic cells was reduced following ara-C treatment 
with a cytotoxicity perspective (40), however, research in the area 
of genotoxicity are lacking, requiring further research to elucidate 
potential mechanisms altering genotoxicity response by leukaemic 
and stromal cells. One study showed ATM-dependent DDR to in-
duce IL-6 secretion by BM stromal cells and subsequent myeloma 
cell chemoresistance (73); probing for the specific DDR cascade may 
reveal targetable mechanisms for future HM therapies (65).
Treatment of cells for co-culture experiments for 1 h at 25 µM 
was selected in line with therapeutic standard dose (100–200 mg/
m2) for a duration that was within cytotoxic limits for genotoxicity 
testing (48,52). Best efforts were made to ensure cytotoxicity was 
at an acceptable level for minimisation of potential false-negative 
and -positive genotoxicity results; viability and RICC > 55  ± 5% 
(48). Cytotoxicity was acceptable in all experimental groups, while 
RICC was acceptable in all groups bar HL-60 cells cultured alone, 
which may increase the possibility of false-negative genotoxicity re-
sults in this group (Table 2). Harvesting cells for the MN assay at 
48 h post-treatment was used for consistency across experimental 
groups, with PD between 1.7 and 3.7 (guidelines recommend 1.5-2 
PD). Additionally, as prior chemotherapy treatment in patients sig-
nificantly hindered BM cell survival in vitro, and that these BM sam-
ples had to be cultured to P4 for MSC purity, there were limited 
cell numbers for multiple co-culture assessments. Therefore, some of 
the 22 patient co-cultures had lower than optimal cells for MN and 
comet analyses (Table 2). Genotoxicity data in this study should, 
therefore, be interpreted with these limitations in mind, with fur-
ther studies investigating extended ara-C treatment times at lower 
doses and post-treatment recovery prior to comet analysis, where 
cell numbers allow. Whilst small changes were seen in terms of in-
creased genotoxicity in MSC and reduced genotoxicity in HL-60, 
we do not know the true physiological impact. Treatment in in vitro 
co-culture models is likely to underestimate effects seen in vivo with 
chemotherapeutic agents, especially as regimens for HMs, particu-
larly AML, feature a combination of agents with different mechan-
isms of action. Additionally, data from co-culture studies are likely 
to be skewed towards the ‘least damaged’ MSC samples, in cells cap-
able of survival to P4.
Sub-analysis of genotoxicity in co-cultures showed minimal 
alteration in MSC by prior in vivo chemotherapeutic treatment 
and AML/MM diagnosis (Supplementary Figure 1, available at 
Mutagenesis Online). However, in HL-60 cells, the most marked pro-
tection was in co-culture with MSC from untreated patients without 
HM as compared to HM untreated/treated patient MSC, and with 
AML–MSC as compared to MM–MSC (Supplementary Figure 1, 
available at Mutagenesis Online). The degree of MSC resistance 
to damage is debated in the literature, with some studies showing 
functional damage to MSC (33,34) and differential mechanisms in 
support of malignancy (13,43,44), while others show resistance to 
chemotherapy (36,59,60). This further adds to the emerging picture 
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that damaged MSC communicate in an aberrant manner; however, 
variations in findings in the literature also highlight the complexity 
of such mechanisms in the BM.
This pilot investigation suggests ‘healthy’ untreated BM-MSC to 
maximally protect malignant HSC from in vitro genotoxicity, per-
haps suggesting aberrant MSC functionality by presence of a HM 
and by previous chemotherapy treatment in patients. One previous 
study showed damaged MSC to be less equipped to support HSC 
growth and migration in vitro (33). Additionally, work by Somaiah 
et al. also showed pre-treated MSC to prevent the efficacy of ara-
C, daunorubicin and vincristine against HL-60 as compared to un-
treated MSC (44).
Investigations into MSC in the HM setting are complex as these 
diseases, AML and MM in particular, are known to invoke signifi-
cant changes in the BM microenvironment (74,75). Distinguishing 
the impact of disease on the BM microenvironment and malig-
nant cells is also challenged by biological variation, demonstrated 
by high heterogeneous response in the co-culture model reflecting 
issues of both inter- and intra-patient heterogeneity in disease diag-
nosis and treatment seen clinically (9,10,76,77). Variations in cell 
behaviour experimentally from AML patients has additionally been 
documented in a number of other studies (14,41,77–79), with com-
pounding factors of our pilot cohort including a mix of malignancies, 
variations in donor age, gender, treatment received (Supplementary 
Table I, available at Mutagenesis Online); consequently life-time 
genotoxic exposures. Future experimentation using this model may 
also benefit from comparing the cellular response between co-culture 
and cells alone, where alone groups use the same cell type cultured in 
both compartments. Investigating direct co-culture effects as well as 
probing for the specific signals conveyed in our indirect model would 
also be an interesting next step. One previous study showed that 
soluble factors (not microvesicles or exosomes) secreted by stromal 
cells were responsible for leukaemic cells protection from ara-C-
induced cytotoxicity (53).
These pilot investigations deserve further work in larger pa-
tient cohorts to confirm the effects seen, as samples were indeed 
limited in the small centre where BM samples were sources, par-
ticularly of some rarer HM subtypes (Supplementary Table I, avail-
able at Mutagenesis Online). The feasibility of such a study with 
finite patient material was confirmed as a secondary aim. Studies in 
this area are further limited by the availability of healthy controls, 
since the ‘no HM’ group in this study cannot be truly considered 
as such due to the nature of the individual undergoing BM investi-
gations for a potential disorder. Malignancies such as AML, while 
crudely grouped by subtype for treatment purposes, have been ac-
knowledged as unique to each individual due to complex genetic 
aberrations (21,80). The very fact that biological and experimental 
heterogeneity are hallmarked in HM investigations, adds to the rele-
vance of the results of this study, which showed some statistically 
significant genotoxicity modulation despite such challenges.
Overall, this pilot study showed reduced ex vivo survival and in-
creased genotoxicity in primary MSC from patients who had under-
gone chemotherapy treatment for a HM, as compared to patient 
cells at diagnosis. Critically, MSC showed some protection of leu-
kaemic HL-60 from spontaneous and ara-C-induced genotoxicity, 
with concurrent increases in MSC genotoxic damage in the pres-
ence of leukaemia cells. These investigations of altered genotoxicity 
in the leukaemic microenvironment are not documented elsewhere 
in the literature to our knowledge, despite the evident impact of 
lasting damage in surviving haematology patients. Additionally, 
the variation in patient results reflects both clinical and biological 
heterogeneity, which challenge the management of HMs. This study 
provides the basis for future research to investigate the mechanisms 
of such bidirectional effects, including the impact of treatment and 
disease. Future work may impact long-term therapeutic efficacy by 
revealing how to reduce genotoxicity and treatment resistance—
some of the foremost issues in HMs and AML specifically today.
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